Neurocrine Biosciences Financial Ratios
NASDAQ: NBIXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Neurocrine Biosciences ratio analysis
Neurocrine Biosciences earned a net margin of 16.7% in FY 2025, up from 14.5% a year earlier. Gross margin was 98.2% compared with a median of 98.8% over the prior 8 years. Return on equity reached 14.7%, meaning Neurocrine Biosciences generated 0.15 dollars of profit for every dollar of shareholders' equity.
At the end of FY 2025, NBIX traded at 30.1 times earnings; across the 8 fiscal years shown, its year-end P/E ranged from 23.0 to 339.6, with a median of 65.0. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Neurocrine Biosciences financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 30.11 | 41.98 | 53.34 | 76.56 | 92.58 | 23.04 | 281.49 | 339.59 | — | — |
| Price / sales | 4.89 | 5.89 | 6.82 | 7.69 | 7.11 | 8.53 | 12.76 | 14.94 | 42.29 | 223.72 |
| Price / book | 4.30 | 5.35 | 5.77 | 6.70 | 5.86 | 7.92 | 15.79 | 14.02 | 18.36 | 10.66 |
| Gross margin | 98.2% | 98.6% | 97.9% | 98.4% | 98.7% | 99.0% | — | 98.9% | 99.2% | 100.0% |
| Operating margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% |
| Net margin | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | 38.9% | 4.7% | 4.7% | -88.2% | -940.6% |
| Free cash flow margin | 26.2% | 23.7% | 19.2% | 21.7% | 20.6% | 20.8% | 16.8% | 17.0% | -62.7% | -735.3% |
| Return on equity (ROE) | 14.7% | 13.2% | 11.2% | 9.0% | 6.5% | 36.2% | 5.8% | 4.4% | -38.3% | -44.8% |
| Return on assets (ROA) | 10.3% | 9.2% | 7.7% | 6.5% | 4.3% | 23.5% | 2.8% | 2.1% | -17.4% | -38.6% |
| Current ratio | 3.39 | 3.40 | 2.45 | 2.70 | 3.96 | 5.45 | 1.47 | 8.36 | 10.20 | 10.21 |
| Revenue growth | 21.4% | 24.8% | 26.8% | 31.3% | 8.4% | 32.7% | 74.7% | 179.2% | 977.5% | -24.1% |
| EPS growth | 41.9% | 33.2% | 58.3% | 69.6% | -77.9% | 966.7% | 77.3% | — | — | — |